Nanobody and Single-Domain Antibody Sequence Listings: Patent Disclosure Requirements

Introduction

The rapid advancement of antibody engineering has transformed the landscape of biologic therapeutics. Among the most significant innovations are nanobodies and single-domain antibodies (sdAbs), which offer unique structural and functional advantages over conventional monoclonal antibodies. Their small size, exceptional stability, high tissue penetration and ease of manufacturing have led to widespread applications in therapeutics, diagnostics, imaging and drug delivery.

As patent filings involving nanobodies continue to increase globally, applicants face an important challenge: ensuring that sequence disclosures satisfy increasingly stringent patent office requirements. Because the novelty and scope of protection often depend on amino acid and nucleotide sequences, inadequate sequence disclosure may result in objections relating to sufficiency of disclosure, written description, enablement, clarity, or claim support.

This article examines the patent disclosure requirements applicable to nanobody and single-domain antibody sequence listings, the impact of WIPO Standard ST.26 and best practices for preparing robust patent applications.

Understanding Nanobodies and Single-Domain Antibodies

Nanobodies are the variable domains derived from heavy-chain-only antibodies naturally found in camelids such as llamas, alpacas and camels. Unlike conventional antibodies, which contain both heavy and light chains, nanobodies consist of a single variable domain capable of independently recognizing antigens.

Single-domain antibodies encompass a broader category that includes:

Although structurally smaller than conventional antibodies (typically 12–15 kDa versus approximately 150 kDa), they often retain high affinity and specificity while offering improved stability under challenging physiological conditions.

Why Sequence Disclosure Matters

Patent protection for biologics increasingly depends upon precise molecular characterization. Unlike small chemical compounds, antibody inventions cannot usually be described solely through functional language.

Patent offices generally require applicants to disclose:

Failure to adequately disclose these sequences may narrow claim scope or jeopardize patent validity.

Importance of Sequence Listings

Sequence listings serve multiple purposes during patent examination.

First, they enable patent examiners to compare claimed sequences with prior art efficiently.

Second, they ensure consistency between the specification and the claimed biological molecules.

Third, publicly available sequence listings facilitate transparency while allowing future researchers to identify claimed biological materials.

Because antibody claims frequently rely on precise sequence identity thresholds (for example, 90%, 95%, or 99% identity), properly formatted sequence listings become central evidence supporting patentability.

WIPO ST.26: The New Global Standard

Since July 1, 2022, patent applications containing nucleotide or amino acid sequences filed under the Patent Cooperation Treaty (PCT) and in many national patent offices must comply with WIPO Standard ST.26.

ST.26 replaced the earlier ST.25 standard and introduced an XML-based sequence listing format designed to improve machine readability and global harmonization.

Major changes include:

Applicants must ensure that sequence listings comply with ST.26 formatting rules before filing.

Sequences That Should Be Included

For nanobody-related inventions, applicants should carefully consider including:

1. Amino Acid Sequences

Every claimed nanobody should include its complete amino acid sequence.

If multiple variants are disclosed, each sequence should receive a unique identifier.

2. Nucleotide Sequences

Where DNA constructs are claimed, nucleotide sequences encoding the nanobody should also be disclosed.

Codon optimization variants may also warrant disclosure if they form part of the invention.

3. CDR Sequences

Complementarity-determining regions often determine antigen specificity.

Disclosure should identify:

Applicants should clearly specify the numbering system used (e.g., Kabat, Chothia, IMGT, or another recognized convention).

4. Framework Regions

Framework sequences frequently contribute to stability and affinity.

If framework mutations are part of the inventive concept, these should be fully described.

5. Engineered Variants

Modern antibody engineering often introduces:

Each significant variant supporting the claims should be adequately disclosed.

Written Description Requirements

Many jurisdictions require applicants to demonstrate possession of the claimed invention at the filing date.

For antibody inventions, merely describing antigen binding may not satisfy written description requirements.

Instead, applicants should disclose:

Broader genus claims are generally more likely to withstand examination when supported by multiple representative examples.

Enablement Considerations

Patent specifications should enable a person skilled in the art to reproduce the claimed invention without undue experimentation.

For nanobody inventions, useful disclosure may include:

Experimental examples significantly strengthen enablement.

Sequence Variants and Percent Identity Claims

Applicants frequently seek protection extending beyond exact disclosed sequences by claiming variants sharing specified sequence identity.

Examples include variants exhibiting:

However, broad identity-based claims require sufficient supporting disclosure demonstrating that variants retain the claimed biological activity.

Patent offices increasingly scrutinize unsupported functional genus claims.

Functional Claiming

Claims directed solely to functional characteristics—for example, “an antibody that binds antigen X”—may face increased examination scrutiny.

Combining functional language with structural limitations generally improves patent robustness.

Typical structural limitations include:

This approach provides clearer boundaries for claim interpretation.

Common Disclosure Pitfalls

Several recurring issues arise in nanobody patent applications:

Careful review before filing can prevent costly prosecution delays.

Best Practices for Patent Applicants

To maximize the strength of nanobody patent applications, applicants should:

Future Trends

The expanding use of artificial intelligence in antibody discovery is expected to increase the complexity of sequence disclosures. Machine-designed antibodies, synthetic libraries, multispecific constructs and computationally optimized variants may require more detailed structural characterization than traditional antibodies.

At the same time, patent offices are likely to continue refining examination practices relating to written description, enablement and sequence-based claiming. Applicants who adopt comprehensive disclosure strategies early in the drafting process will be better positioned to secure broad and enforceable patent protection.

Conclusion

Nanobodies and single-domain antibodies represent one of the fastest-growing segments of biologic innovation. Their commercial value makes robust patent protection essential, but such protection depends heavily on the quality of sequence disclosure.

Comprehensive sequence listings, compliance with WIPO ST.26, accurate structural characterization and well-supported functional data collectively strengthen patent applications and reduce prosecution risks. By integrating scientific rigor with careful patent drafting, applicants can maximize the likelihood of obtaining durable protection for these valuable biologic inventions.

Leave a Reply

Your email address will not be published. Required fields are marked *